Peripheral nerve injury is a salient clinical problem but lacks successful treatment schemes. Here we show the protective mechanism of hypoxia-induced Schwann cells-derived extracellular vesicles (H-E Show more
Peripheral nerve injury is a salient clinical problem but lacks successful treatment schemes. Here we show the protective mechanism of hypoxia-induced Schwann cells-derived extracellular vesicles (H-EVs) carrying lncRNA TNXA-PS1 in peripheral nerve injury. EVs isolated from RSC96 cells undergo hypoxia (H) induction. Sciatic nerve injury is induced in rats, and the animals are evaluated by Sciatic Nerve Function Index, gastrocnemius muscle mass ratio, hematoxylin & eosin stain, and sensory recovery tests. LncRNA TNXA-PS1, miR-338-3p, and EGFL7 expression is tested by RT-qPCR and Western blot. Proliferation, migration, and angiogenesis of H-EVs- treated endothelial cells are assessed by CCK-8, EdU staining, transwell, and tubular formation assays. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NF200, P0, CD31, and vascular endothelial growth factor (VEGF) are detected. Dual luciferase assay analyzes the binding of lncRNA TNXA-PS1, miR-338-3p, and EGFL7. Results reveal that H-EVs alleviate gastrocnemius muscle atrophy, facilitate motor function recovery, and elevate NGF, BDNF, NF200, P0, CD31, and VEGF in tissues. H-EVs promote endothelial cell proliferation, migration, and tubular formation. Mechanistically, H-EVs carry lncRNA TNXA-PS1 into endothelial cells, thus upregulating EGFL7 expression by sponging miR-338-3p. Collectively, H-EVs carrying lncRNA TNXA-PS1 promote angiogenesis and nerve function recovery post sciatic nerve injury via miR-338-3p/EGFL7 axis. Show less
Post-stroke neurogenic bladder dysfunction impairs patients' quality of life, yet current treatments offer limited effectiveness. This study investigated the therapeutic effects and underlying mechani Show more
Post-stroke neurogenic bladder dysfunction impairs patients' quality of life, yet current treatments offer limited effectiveness. This study investigated the therapeutic effects and underlying mechanisms of human amniotic fluid stem cell-derived extracellular vesicle (hAFSC-EV) on bladder dysfunction and neurovascular plasticity after cerebral ischemia. Thirty-six female rats underwent bilateral ovariectomy and were assigned to sham-operated or 90-min middle cerebral artery occlusion (MCAO) groups, with or without a single injection of hAFSC-EVs. Magnetic resonance imaging (MRI), cystometry, blood-brain barrier (BBB) permeability, and markers of neurogenesis and angiogenesis in ischemic brain were assessed. Bladder levels of brain-derived neurotrophic factor (BDNF), β3-adrenoceptor, adenylate cyclase, and M2- and M3-muscarinic receptors were evaluated at 7 and 28 days post-MCAO or sham-operation. Compared with untreated rats, hAFSC-EV treatment significantly reduced cerebral infarct volume and BBB leakage, and enhanced microvessel and vascular density, along with angiogenesis. Neural markers such as BDNF, nestin, and doublecortin were significantly upregulated at 7 and/or 28 days post-MCAO. hAFSC-EV treatment ameliorated MCAO-induced bladder dysfunction by reducing peak voided volume, intercontraction interval, and bladder capacity, along with improving residual urine volume. hAFSC-EV treatment significantly increased bladder expression of BDNF and M3-muscarinic receptors, and recovers the expressions of M2, β3-adrenoceptor, and adenylate cyclase to near control levels at 7 and 28 days post-MCAO. hAFSC-EV treatment improves neurogenic bladder dysfunction and cerebral ischemia post-MCAO, potentially through reducing infarct volume and BBB disruption, enhancing neurogenesis and angiogenesis in the ischemic brain, and modulating the expression of bladder BDNF, β3-adrenoceptor, adenylate cyclase and muscarinic receptors. Show less
Traumatic injuries to the central nervous system (CNS), including traumatic brain injury (TBI) and spinal cord injury (TSCI), are among the leading causes of disability and mortality worldwide. The va Show more
Traumatic injuries to the central nervous system (CNS), including traumatic brain injury (TBI) and spinal cord injury (TSCI), are among the leading causes of disability and mortality worldwide. The valuable effect of extracellular vesicles (EVs) from mesenchymal stem cells (MSCs-EVs) in the treatment of traumatic injuries has been documented. EVs, including exosomes, are heterogeneous cell-derived particles, contributing to cell communication through exchanging biomolecules between cells. MSCs-EVs can regulate physiological processes, including synaptic plasticity, neuronal firing, development and repair of myelin sheath, neuroprotection, advancement of neuroinflammation, and extent and elimination of protein aggregates. However, natural MSCs-EVs have some limitations. Recent advancements have shown that MSCs-EVs can be engineered for effective and targeted therapy in traumatic injuries. Most experiments have focused on miRNA-engineered MSCs-EVs to boost their therapeutic effects. In TBI models, MSCs-EVs have been modified to deliver miR-124, miR-17-92, miR-124-3p, or BDNF, whereas in TSCI models, EVs have been engineered with miR-216a-5p, miR-146a-5p, miR-133b, miR-146, miR-138-5p, miR-29b, miR-181c, lncGm37494, siRNAs, or Shh. Results from in vitro and animal studies show the substantial potential of engineered MSCs-EVs for protection, neuroregeneration, and functional recovery. But challenges remain in translating these outcomes into clinical trials, including standardization, safety, and delivery efficacy. In this review, we summarize recent knowledge on MSCs-EVs, focusing on their mechanisms of action in CNS traumatic injuries, and discuss the latest developments, inherent advantages, and potential hurdles in evolving these groundbreaking therapeutic approaches. Show less